|
Hirayama E, Sasao N, Yoshimasu S, Kim J.
K252a, an indrocarbazole derivative, causes the membrane of myoblasts to
enter a fusion-capable state.
Biochem Biophys Res Commun. 2001 Aug 3;285(5):1237-43.
Institute of Molecular and Cellular Biology for Pharmaceutical
Sciences, Kyoto Pharmaceutical University, 1, Shichonocho,
Misasagi, Yamashina-ku, Kyoto, 607-8412, Japan.
K252a, an indrocarbazole derivative and protein kinase
inhibitor, is reported to promote myogenic differentiation in C2
mouse myoblasts. We examined the effects of K252a on QM-RSV
cells, quail myoblasts transformed with a temperature-sensitive
mutant of Rous sarcoma virus. K252a promoted myotube formation
of QM-RSV cells. Presumptive QM-RSV cells also formed
multinucleated cells when exposed to K252a. However, the
expression of myogenin, a muscle regulatory factor, was not
stimulated in the presence of the drug, suggesting that it
promotes membrane fusion but not myogenic differentiation. To
confirm the promotion of membrane fusion by K252a, presumptive
C2 cells, which are strongly resistant to HVJ-mediated cell
fusion, were fused by HVJ (Sendai virus) after K252a treatment.
Presumptive C2 cells treated with K252a fused with HVJ,
demonstrating that K252a causes the cells to enter a
fusion-capable state. The amount of membrane cholesterol, a
factor that decreases membrane fluidity, fell in K252a-treated
C2 cells. The results suggest that a decrease of membrane
cholesterol is a cause of the change that renders myoblast
membrane susceptible to fusion in the presence of K252a.
Copyright 2001 Academic Press.
PMID: 11478789
|
